State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
Cell Commun Signal. 2024 Jul 29;22(1):383. doi: 10.1186/s12964-024-01757-w.
Acute hypobaric hypoxia-induced brain injury has been a challenge in the health management of mountaineers; therefore, new neuroprotective agents are urgently required. Meldonium, a well-known cardioprotective drug, has been reported to have neuroprotective effects. However, the relevant mechanisms have not been elucidated. We hypothesized that meldonium may play a potentially novel role in hypobaric hypoxia cerebral injury.
We initially evaluated the neuroprotection efficacy of meldonium against acute hypoxia in mice and primary hippocampal neurons. The potential molecular targets of meldonium were screened using drug-target binding Huprot™ microarray chip and mass spectrometry analyses after which they were validated with surface plasmon resonance (SPR), molecular docking, and pull-down assay. The functional effects of such binding were explored through gene knockdown and overexpression.
The study clearly shows that pretreatment with meldonium rapidly attenuates neuronal pathological damage, cerebral blood flow changes, and mitochondrial damage and its cascade response to oxidative stress injury, thereby improving survival rates in mice brain and primary hippocampal neurons, revealing the remarkable pharmacological efficacy of meldonium in acute high-altitude brain injury. On the one hand, we confirmed that meldonium directly interacts with phosphoglycerate kinase 1 (PGK1) to promote its activity, which improved glycolysis and pyruvate metabolism to promote ATP production. On the other hand, meldonium also ameliorates mitochondrial damage by PGK1 translocating to mitochondria under acute hypoxia to regulate the activity of TNF receptor-associated protein 1 (TRAP1) molecular chaperones.
These results further explain the mechanism of meldonium as an energy optimizer and provide a strategy for preventing acute hypobaric hypoxia brain injury at high altitudes.
急性低压缺氧诱导的脑损伤一直是登山者健康管理中的一个挑战;因此,迫切需要新的神经保护剂。 meldonium 是一种著名的心脏保护药物,据报道具有神经保护作用。然而,相关机制尚未阐明。我们假设 meldonium 可能在低压缺氧性脑损伤中发挥潜在的新作用。
我们首先评估了 meldonium 对小鼠和原代海马神经元急性缺氧的神经保护作用。使用药物-靶标结合 Huprot ™微阵列芯片和质谱分析筛选 meldonium 的潜在分子靶标,然后通过表面等离子体共振(SPR)、分子对接和下拉实验进行验证。通过基因敲低和过表达来探索这种结合的功能效应。
研究清楚地表明,预先给予 meldonium 可迅速减轻神经元病理损伤、脑血流变化和线粒体损伤及其级联反应的氧化应激损伤,从而提高小鼠大脑和原代海马神经元的存活率,显示 meldonium 在急性高原脑损伤中的显著药理作用。一方面,我们证实 meldonium 直接与磷酸甘油酸激酶 1(PGK1)相互作用,以促进其活性,从而改善糖酵解和丙酮酸代谢,以促进 ATP 产生。另一方面, meldonium 还通过 PGK1 在急性缺氧下向线粒体转移来改善线粒体损伤,从而调节肿瘤坏死因子受体相关蛋白 1(TRAP1)分子伴侣的活性。
这些结果进一步解释了 meldonium 作为能量优化剂的作用机制,并为预防高原急性低压缺氧性脑损伤提供了一种策略。